Triple drug attack on melanoma: new trial hopes to boost surgery success
NCT ID NCT07511036
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests three immune-boosting drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery in 20 people with advanced but removable melanoma. The goal is to see if the combination is safe and can shrink tumors, potentially improving outcomes. Participants must have stage III or limited stage IV melanoma that can be fully removed by surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab, fianlimab, and ipilimumab (immune-boosting drugs given by IV)
What this could lead to
If successful, this combination could shrink melanoma tumors before surgery, potentially improving long-term outcomes for patients with advanced but removable skin cancer.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The triple drug combo may cause severe side effects, and it's not yet known if it works better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact